Cynvenio Biosystems | GenomeWeb

Cynvenio Biosystems

The study will join Cynvenio's ClearID test with ATGen's NK Vue test to detect cancer recurrence in previously treated triple-negative breast cancer patients.

The firm said that theUSfederal government recognizes the CAP accreditation program as being equal to or more stringent than its own inspection program.

The company plans to expand its CLIA testing and complete a major study in theUS, as it moves forward to open a joint venture inChinathat will support further commercial expansion and clinical utility research.

The partnership will leverage Cynvenio's ClearID liquid biopsy test, which detects tumor cells from blood samples.

The firm will use the financing to support clinical development and commercialization of its CTC and ctDNA liquid biopsy technology.

Cynvenio's LiquidBiopsy platform is designed to extract and isolate circulating tumor cells from a blood draw and prepare them for imaging and genomic analysis.

NEW YORK (GenomeWeb) — Diagnologix, a year-old startup developing microbubble-based sample prep technology, has been awarded a $25,000 grant as part of the company's acceptance into I-Corps, a recently established business-development program from the National Institutes of Health and National Sc

NEW YORK (GenomeWeb) – Cynvenio Biosystems today announced the launch of an early access program for its LiquidBiopsy Rare Cell Isolation Platform.

NEW YORK (GenomeWeb News) – CollabRx said today that it has signed a multi-year agreement with cancer diagnostics firm Cynvenio Biosystems, under which Cynvenio will use CollabRx's technology and content resources to interpret data from the sequencing-based tests its provides.

Pages

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.